Vimarsana
Biggest News Aggregation in the World

Page 14 - Cameron Durrant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cameron Durrant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cameron Durrant Today - Breaking & Trending Today

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenziluma - Vimarsana News

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenziluma

Search jobs 10-Jan-2021 Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 BURLINGAME, Calif. & CHICAGO--(BUSINESS WIRE)--Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced that they are partnering to make lenzilu...

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 - Vimarsana News

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

News Category Global Banking & Finance Reviews Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab„¢, and EVERSANA, a pioneer of next-generation services to the global life sciences i...

Humanigen to Present at J.P. Morgan Healthcare Conference - Vimarsana News

Humanigen to Present at J.P. Morgan Healthcare Conference

Humanigen to Present at J.P. Morgan Healthcare Conference (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ˜cytokine storm with its lead drug candidate, lenzilumab„¢, today announced that the Companys management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021. Cameron Durrant, MD, MBA, chief executive officer of Humanigen, Dale Chappell, MD, MBA, chief scientific officer, and Timothy Morris, chi...

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme - Press Release - Vimarsana News

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme - Press Release

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME, Calif.--(Business Wire)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is...

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme - Vimarsana News

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM). Ifabotuzumab, or ifab, is the Company’s proprietary anti-EphA3 monoclonal antibody. This trial is s...